Another systematic review and meta-analysis of 22 randomized controlled trials also supported these findings, showing that SGLT2 inhibitor use in patients with DM, chronic kidney disease (CKD), or (HF) was associated with a lower incidence of AF and embolic stroke [260]. The gene discussed is SLC5A2; the disease is chronic kidney disease.